Finance

Beta
Lists
AKUMS:NSE
Akums Drugs and Pharmaceuticals Ltd
₹553.05
-0.44%
(-2.45) 1D
Jun 5, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AKUMS...
Open
₹559.50
High
₹564.90
Low
₹548.30
Mkt. cap
84.67B
Avg. vol.
234.43K
Volume
96.12K
Dividend
0.18%
Quarterly dividend
₹0.25
Ex-dividend date
Jul 3, 2026
P/E ratio
33.18
52-wk high
₹597.00
52-wk low
₹409.30
EPS
₹16.67
No. of employees
8K
Open
₹559.50
High
₹564.90
Low
₹548.30
Mkt. cap
84.67B
Avg. vol.
234.43K
Volume
96.12K
Dividend
0.18%
Quarterly dividend
₹0.25
Ex-dividend date
Jul 3, 2026
P/E ratio
33.18
52-wk high
₹597.00
52-wk low
₹409.30
EPS
₹16.67
No. of employees
8K
News stories
From sources across the web
Profile
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024. Wikipedia
About Akums Drugs and Pharmaceuticals Ltd
CEO-
Employees7.54K
Founded2004
Headquarters-
SectorHealth care
Websiteakums.in
Last report
May 18, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
11.58B / 11.69B
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
10.24B
10.18B
11.60B
11.58B
Cost of goods sold
5.82B
5.93B
6.79B
6.60B
Cost of revenue
5.82B
5.93B
6.79B
6.60B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.76B
1.89B
1.89B
1.99B
Operating expense
3.50B
3.68B
3.74B
3.86B
Total operating expenses
9.32B
9.61B
10.52B
10.46B
Operating income
920.50M
566.12M
1.07B
1.12B
Other non operating income
267.31M
323.65M
343.28M
353.01M
EBT including unusual items
956.46M
656.73M
995.66M
1.21B
EBT excluding unusual items
956.46M
656.73M
1.18B
1.23B
Income tax expense
309.61M
229.77M
318.92M
398.74M
Effective tax rate
32.37%
34.99%
32.03%
32.89%
Other operating expenses
1.37B
1.41B
1.45B
1.47B
Net income
634.75M
407.83M
663.17M
846.13M
Net profit margin
6.20%
4.01%
5.72%
7.31%
Earnings per share
-
2.66
5.14
-
Interest and investment income
-
-
-
-
Interest expense
-231.35M
-233.04M
-237.42M
-238.92M
Net interest expenses
-231.35M
-233.04M
-237.42M
-238.92M
Depreciation and amortization charges
369.20M
378.64M
396.49M
401.18M
EBITDA
1.27B
940.04M
1.42B
1.50B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer